1
|
Li J, Feng W, Lu H, Wei Y, Ma S, Wei L, Liu Q, Zhao J, Wei Q, Yao J. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation. J Cell Physiol 2019; 234:12663-12675. [PMID: 30536376 DOI: 10.1002/jcp.27875] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 11/15/2018] [Indexed: 01/03/2023]
Abstract
In addition to being used to treat malaria, artemisinin (Art) can be used as an anti-inflammatory and antitumor agent. In this study, we evaluated the effects of Art on osteoclast formation and activation and on the development of breast cancer cells in bone. To evaluate the effect of Art on osteoclast differentiation in vitro, we treated bone marrow-derived macrophages (BMMs) with various concentrations of Art and evaluated the expression of genes and proteins involved in osteoclast formation. We also performed cell counting kit-8 assays to evaluate the toxicity of Art in BMMs and MDA-MB-231 cells. We also performed Transwell assays, wound-healing assays, colony formation assays, and cell apoptosis assays to evaluate the effect of Art in MDA-MB-231 cells. We also evaluated the effect of Art in an in vivo osteoclast bone resorption assay using a nude mouse model. We demonstrated that Art inhibits the differentiation and establishment of osteoclasts even though Art is not toxic to osteoclasts. In addition, Art reduced expression of genes involved in osteoclast formation and inhibited osteoclast bone resorption in a concentration-dependent manner. Based on our data, we believe that Art can inhibit proliferation of breast cancer cells by activating apoptosis pathways, and inhibit osteoclast formation and differentiation by inhibiting activation of cathepsin K, ATPase H+ transporting V0 subunit D2, nuclear factor of activated T cells 1, calcitonin receptor, and tartrate-resistant acid phosphatase and by inhibiting nuclear factor-κB activation.
Collapse
Affiliation(s)
- Jia Li
- Department of Pathology, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Wenyu Feng
- Department of Orthopaedic Surgery, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
- Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, People's Republic of China
| | - Huiping Lu
- Department of Pathology, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Yan Wei
- Department of Pathology, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Shiting Ma
- Department of Orthopaedic Surgery, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Linfeng Wei
- Department of Orthopaedic Surgery, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
- Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, People's Republic of China
| | - Qian Liu
- Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, People's Republic of China
- Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, People's Republic of China
| | - Jinmin Zhao
- Department of Orthopaedic Surgery, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
- Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, People's Republic of China
- Bone and Joint Surgery, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
- Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, People's Republic of China
| | - Qingjun Wei
- Department of Orthopaedic Surgery, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
- Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, People's Republic of China
- Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, People's Republic of China
| | - Jun Yao
- Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, People's Republic of China
- Bone and Joint Surgery, The First Affliated Hospital of Guangxi Medical University, Nanning, People's Republic of China
- Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, People's Republic of China
| |
Collapse
|
2
|
Klopotowska D, Matuszyk J, Wietrzyk J. Steroid hormone calcitriol and its analog tacalcitol inhibit miR-125b expression in a human breast cancer MCF-7 cell line. Steroids 2019; 141:70-75. [PMID: 30503385 DOI: 10.1016/j.steroids.2018.11.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 11/02/2018] [Accepted: 11/19/2018] [Indexed: 11/21/2022]
Abstract
MiR-125b belongs to the class of microRNAs, which are short endogenous non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. Recently, it was reported that miR-125b was found to promote migration and invasion of MCF-7 cells and was involved in chemotherapeutic resistance. Decreasing miR-125b expression would have potential therapeutic significance in preventing dissemination of breast cancer cells. The objective of this study was to evaluate miR-125b expression levels in MCF-7 cells following treatment with 1,25-dihydroxyvitamin D3 (calcitriol) and 1,24-dihydroxyvitamin D3 (tacalcitol), active metabolite and synthetic analog of vitamin D3, respectively. We found that treatment with both calcitriol and tacalcitol caused a decrease in miR-125b expression. In addition, treatment with calcitriol and tacalcitol resulted in an increase in the level of pro-apoptotic BAK1 protein encoded by the target gene of miR-125b. We are discussing the putative mechanism of inhibition of the miR-125b expression by vitamin D receptor (VDR) agonists and we suggest that calcitriol and tacalcitol may be used as a miR-125b inhibitor in breast cancer cells expressing VDR.
Collapse
Affiliation(s)
- Dagmara Klopotowska
- Laboratory of Experimental Anticancer Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 R. Weigla Street, 53-114 Wroclaw, Poland.
| | - Janusz Matuszyk
- Laboratory of Signal Transduction Molecules, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 R. Weigla Street, 53-114 Wroclaw, Poland.
| | - Joanna Wietrzyk
- Laboratory of Experimental Anticancer Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 R. Weigla Street, 53-114 Wroclaw, Poland.
| |
Collapse
|
3
|
Brosseau C, Durand M, Colas L, Durand E, Foureau A, Cheminant MA, Bouchaud G, Castan L, Klein M, Magnan A, Brouard S. CD9 + Regulatory B Cells Induce T Cell Apoptosis via IL-10 and Are Reduced in Severe Asthmatic Patients. Front Immunol 2018; 9:3034. [PMID: 30622536 PMCID: PMC6308143 DOI: 10.3389/fimmu.2018.03034] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 12/07/2018] [Indexed: 12/28/2022] Open
Abstract
CD9 was recently identified as a marker of murine IL-10-competent regulatory B cells. Functional impairments or defects in CD9+ IL-10-secreting regulatory B cells are associated with enhanced asthma-like inflammation and airway hyperresponsiveness. In mouse models, all asthma-related features can be abrogated by CD9+ B cell adoptive transfer. We aimed herein to decipher the profiles, features, and molecular mechanisms of the regulatory properties of CD9+ B cells in human and mouse. The profile of CD9+ B cells was analyzed using blood from severe asthmatic patients and normal and asthmatic mice by flow cytometry. The regulatory effects of mouse CD9+ B cells on effector T cell death, cell cycle arrest, apoptosis, and mitochondrial depolarization were determined using yellow dye, propidium iodide, Annexin V, and JC-1 staining. MAPK phosphorylation was analyzed by western blotting. Patients with severe asthma and asthmatic mice both harbored less CD19+CD9+ B cells, although these cells displayed no defect in their capacity to induce T cell apoptosis. Molecular mechanisms of regulation of CD9+ B cells characterized in mouse showed that they induced effector T cell cycle arrest in sub G0/G1, leading to apoptosis in an IL-10-dependent manner. This process occurred through MAPK phosphorylation and activation of both the intrinsic and extrinsic pathways. This study characterizes the molecular mechanisms underlying the regulation of CD9+ B cells to induce effector T cell apoptosis in mice and humans via IL-10 secretion. Defects in CD9+ B cells in blood from patients with severe asthma reveal new insights into the lack of regulation of inflammation in these patients.
Collapse
Affiliation(s)
- Carole Brosseau
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie, CHU Nantes, Nantes, France.,Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, Université de Nantes, Nantes, France.,Institut du Thorax, CHU de Nantes, Nantes, France
| | - Maxim Durand
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie, CHU Nantes, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - Luc Colas
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie, CHU Nantes, Nantes, France.,Institut du Thorax, CHU de Nantes, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - Eugénie Durand
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie, CHU Nantes, Nantes, France
| | - Aurore Foureau
- Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, Université de Nantes, Nantes, France.,Institut du Thorax, CHU de Nantes, Nantes, France
| | - Marie-Aude Cheminant
- Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, Université de Nantes, Nantes, France
| | - Gregory Bouchaud
- Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, Université de Nantes, Nantes, France.,INRA Centre Angers-Nantes, Nantes, France
| | - Laure Castan
- Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, Université de Nantes, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France.,INRA Centre Angers-Nantes, Nantes, France
| | - Martin Klein
- Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, Université de Nantes, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - Antoine Magnan
- Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, Université de Nantes, Nantes, France.,Institut du Thorax, CHU de Nantes, Nantes, France
| | - Sophie Brouard
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie, CHU Nantes, Nantes, France.,Centre d'Investigation Clinique (CIC) Biothérapie, CHU Nantes, Nantes, France
| |
Collapse
|
4
|
Lv JM, Chen L, Gao Y, Huang H, Pan XW, Liu X, Chen M, Qu FJ, Li L, Wang JK, Cui XG, Xu DF. PPP5C promotes cell proliferation and survival in human prostate cancer by regulating of the JNK and ERK1/2 phosphorylation. Onco Targets Ther 2018; 11:5797-5809. [PMID: 30254472 PMCID: PMC6140725 DOI: 10.2147/ott.s161280] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background Prostate cancer (PCa) is one of the most common malignancies and a major leading cause of cancer-related deaths in males. And it is necessary to explore new molecular targets to enhance diagnosis and treatment level of the PCa. Serine/threonine protein phosphatase 5 (PPP5C) is a vital molecule that Involve in complex cell physiological activity. Purpose The objective of this study was to detecte the expression level of PPP5C in the tissue of prostate cancer patients and further discussed the PPP5C biological function and mechanisms on the PCa. Methods The expression level of PPP5C was analyzed by immunohistochemistry and ONCOM-INE datasets. Lentivirus-mediated short hairpin RNA (shRNA) was constructed to silence the expression of PPP5C in prostate cancer cell. Cell viability and proliferation were measured using MTT and colony formation, and the cell cycle and apoptosis was analyszed by flow cytometry. The changes of downstream protein level and protein phosphorylation level were detected by western blot. Results PPP5C was highly expressed in PCa tissue as analyzed by immunohistochemistry and ONCOMINE datasets. PPP5C Knockdown inhibited cell proliferation and colony formation in PCa cells. Flow cytometry analysis showed that DU145, PC3 and 22RV1 PCa cells deprived of PPP5C were arrested in G0/G1 phase and became apoptotic. Western blot analysis indicated that PPP5C knockdown could promote JNK and ERK phosphorylation. Conclusion Our study indicated that the PPP5C may become a new potential diagnostic biomarker and therapeutic target for the PCa.
Collapse
Affiliation(s)
- Jian-Min Lv
- Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China, .,Department of Urinary Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.,Department of Urinary Surgery, Third Affiliated Hospital, Second Military Medical University, Shanghai 201805, China,
| | - Lu Chen
- Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China,
| | - Yi Gao
- Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China,
| | - Hai Huang
- Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China, .,Department of Urinary Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.,Department of Urinary Surgery, Third Affiliated Hospital, Second Military Medical University, Shanghai 201805, China,
| | - Xiu-Wu Pan
- Department of Urinary Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.,Department of Urinary Surgery, Third Affiliated Hospital, Second Military Medical University, Shanghai 201805, China,
| | - Xi Liu
- Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China,
| | - Ming Chen
- Department of Urinary Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
| | - Fa-Jun Qu
- Department of Urinary Surgery, Third Affiliated Hospital, Second Military Medical University, Shanghai 201805, China,
| | - Lin Li
- Department of Urinary Surgery, Third Affiliated Hospital, Second Military Medical University, Shanghai 201805, China,
| | - Jun-Kai Wang
- Department of Urinary Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
| | - Xin-Gang Cui
- Department of Urinary Surgery, Third Affiliated Hospital, Second Military Medical University, Shanghai 201805, China, .,Department of Urinary Surgery, Gongli Hospital, Second Military Medical University, Shanghai 200135, China,
| | - Dan-Feng Xu
- Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China,
| |
Collapse
|
5
|
Yang J, Zhu S, Lin G, Song C, He Z. Vitamin D enhances omega-3 polyunsaturated fatty acids-induced apoptosis in breast cancer cells. Cell Biol Int 2017. [DOI: 10.1002/cbin.10806] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Jing Yang
- State Key Laboratory of Food Science and Technology; School of Food Science and Technology; Jiangnan University; Wuxi 214122 China
- Synergistic Innovation Center for Food Safety and Nutrition; Jiangnan University; Wuxi 214122 China
| | - Shenglong Zhu
- State Key Laboratory of Food Science and Technology; School of Food Science and Technology; Jiangnan University; Wuxi 214122 China
- Synergistic Innovation Center for Food Safety and Nutrition; Jiangnan University; Wuxi 214122 China
| | - Guangxiao Lin
- State Key Laboratory of Food Science and Technology; School of Food Science and Technology; Jiangnan University; Wuxi 214122 China
- Synergistic Innovation Center for Food Safety and Nutrition; Jiangnan University; Wuxi 214122 China
| | - Ci Song
- State Key Laboratory of Food Science and Technology; School of Food Science and Technology; Jiangnan University; Wuxi 214122 China
- Synergistic Innovation Center for Food Safety and Nutrition; Jiangnan University; Wuxi 214122 China
| | - Zhao He
- State Key Laboratory of Food Science and Technology; School of Food Science and Technology; Jiangnan University; Wuxi 214122 China
- Synergistic Innovation Center for Food Safety and Nutrition; Jiangnan University; Wuxi 214122 China
- School of Medicine; Jiangnan University; Wuxi 214122 China
| |
Collapse
|
6
|
Gocek E, Studzinski GP. DNA Repair in Despair-Vitamin D Is Not Fair. J Cell Biochem 2016; 117:1733-44. [PMID: 27122067 DOI: 10.1002/jcb.25552] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 03/24/2016] [Indexed: 02/06/2023]
Abstract
The role of vitamin D as a treatment option for neoplastic diseases, once considered to have a bright future, remains controversial. The preclinical studies discussed herein show compelling evidence that Vitamin D Derivatives (VDDs) can convert some cancer and leukemia cells to a benign phenotype, by differentiation/maturation, cell cycle arrest, or induction of apoptosis. Furthermore, there is considerable, though still evolving, knowledge of the molecular mechanisms underlying these changes. However, the attempts to clearly document that the treatment outcomes of human neoplastic diseases can be positively influenced by VDDs have been, so far, disappointing. The clinical trials to date of VDDs, alone or combined with other agents, have not shown consistent results. It is our contention, shared by others, that there were limitations in the design or execution of these trials which have not yet been fully addressed. Based on the connection between upregulation of JNK by VDDs and DNA repair, we propose a new avenue of attack on cancer cells by increasing the toxicity of the current, only partially effective, cancer chemotherapeutic drugs by combining them with VDDs. This can impair DNA repair and thus kill the malignant cells, warranting a comprehensive study of this novel concept. J. Cell. Biochem. 117: 1733-1744, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Elżbieta Gocek
- Faculty of Biotechnology, Department of Proteins Biotechnology, University of Wrocław, Joliot-Curie 14A Street, Wrocław 50-383, Poland
| | - George P Studzinski
- Department of Pathology and Laboratory Medicine, New Jersey Medical School, Rutgers, The State University of New Jersey, 185 South Orange Avenue, Newark, 07103, New Jersey, USA
| |
Collapse
|
7
|
Li H, Tang Z, Zhu H, Ge H, Cui S, Jiang W. Proteomic study of benign and malignant pleural effusion. J Cancer Res Clin Oncol 2016; 142:1191-200. [PMID: 26945985 DOI: 10.1007/s00432-016-2130-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2015] [Accepted: 02/08/2016] [Indexed: 12/18/2022]
Abstract
BACKGROUND Lung adenocarcinoma can easily cause malignant pleural effusion which was difficult to discriminate from benign pleural effusion. Now there was no biomarker with high sensitivity and specificity for the malignant pleural effusion. PURPOSE This study used proteomics technology to acquire and analyze the protein profiles of the benign and malignant pleural effusion, to seek useful protein biomarkers with diagnostic value and to establish the diagnostic model. METHODS We chose the weak cationic-exchanger magnetic bead (WCX-MB) to purify peptides in the pleural effusion, used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) to obtain peptide expression profiles from the benign and malignant pleural effusion samples, established and validated the diagnostic model through a genetic algorithm (GA) and finally identified the most promising protein biomarker. RESULTS A GA diagnostic model was established with spectra of 3930.9 and 2942.8 m/z in the training set including 25 malignant pleural effusion and 26 benign pleural effusion samples, yielding both 100 % sensitivity and 100 % specificity. The accuracy of diagnostic prediction was validated in the independent testing set with 58 malignant pleural effusion and 34 benign pleural effusion samples. Blind evaluation was as follows: the sensitivity was 89.6 %, specificity 88.2 %, PPV 92.8 %, NPV 83.3 % and accuracy 89.1 % in the independent testing set. The most promising peptide biomarker was identified successfully: Isoform 1 of caspase recruitment domain-containing protein 9 (CARD9), with 3930.9 m/z, was decreased in the malignant pleural effusion. CONCLUSIONS This model is suitable to discriminate benign and malignant pleural effusion and CARD9 can be used as a new peptide biomarker.
Collapse
Affiliation(s)
- Hongqing Li
- Department of Respiratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China
| | - Zhonghao Tang
- Department of Respiratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China
| | - Huili Zhu
- Department of Respiratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China.
| | - Haiyan Ge
- Department of Respiratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China
| | - Shilei Cui
- Department of Respiratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China
| | - Weiping Jiang
- Department of Respiratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China
| |
Collapse
|
8
|
SUN XIAOLI, JIA YU, WEI YUANYU, LIU SHUAI, YUE BAOHONG. Gene expression profiling of HL-60 cells following knockdown of nucleostemin using DNA microarrays. Oncol Rep 2014; 32:739-47. [DOI: 10.3892/or.2014.3240] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Accepted: 04/29/2014] [Indexed: 11/05/2022] Open
|
9
|
Picotto G, Liaudat AC, Bohl L, Tolosa de Talamoni N. Molecular aspects of vitamin D anticancer activity. Cancer Invest 2012; 30:604-14. [PMID: 22963190 DOI: 10.3109/07357907.2012.721039] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Environment may influence the development and prevention of cancer. Calcitriol has been associated with calcium homeostasis regulation. Many epidemiological, biochemical, and genetic studies have shown non-classic effects of vitamin D, such as its involvement in the progression of different cancers. Although vitamin D induces cellular arrest, triggers apoptotic pathways, inhibits angiogenesis, and alters cellular adhesion, the precise mechanisms of its action are still not completely established. This article will present a revision about the molecular aspects proposed to be involved in the anticancer action of calcitriol. Adequate levels of vitamin D to prevent cancer development will also be discussed.
Collapse
Affiliation(s)
- Gabriela Picotto
- Cátedra de Bioquímica y Biología Molecular, Ciencias Médicas, Ciudad Universitaria, Córdoba, Argentina.
| | | | | | | |
Collapse
|
10
|
Vanoirbeek E, Krishnan AV, Eelen IG, Verlinden L, Bouillon R, Feldman D, Verstuyf A. The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃. Best Pract Res Clin Endocrinol Metab 2011; 25:593-604. [PMID: 21872801 PMCID: PMC3164534 DOI: 10.1016/j.beem.2011.05.001] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Various epidemiological studies have shown an aetiological link between vitamin D deficiency and cancer incidence. The active metabolite of vitamin D, 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], has potent anti-cancer activities both in vitro and in vivo. These anti-cancer effects are attained by regulating the transcription of numerous genes that are involved in different pathways to reduce tumorigenesis and are dependent on the cancer cell type. Besides reducing cell growth and inducing apoptosis, 1,25(OH)₂D₃ also inhibits angiogenesis and metastasis. Moreover, its potency to inhibit inflammation also contributes to its anti-tumoral activity. Here, we report the different ways in which 1,25(OH)₂D₃ interferes with the malignant processes that are activated in cancer cells.
Collapse
Affiliation(s)
- Els Vanoirbeek
- Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Herestraat 49 bus 901 O&NI, Leuven, Belgium, tel. +32 16 347145, fax +32 16 345934
| | - Aruna V Krishnan
- Dept. of Medicine, Division of Endocrinology, Stanford University School of Medicine 300 Pasteur Drive, Stanford, CA 94305-5103, USA, tel: 650-725-2910, fax: 650-725-7085
| | - Ir Guy Eelen
- Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Herestraat 49 bus 901 O&NI, Leuven, Belgium, tel. +32 16 347145, fax +32 16 345934
| | - Lieve Verlinden
- Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Herestraat 49 bus 901 O&NI, Leuven, Belgium, tel. +32 16 347145, fax +32 16 345934
| | - Roger Bouillon
- Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Herestraat 49 bus 901 O&NI, Leuven, Belgium, tel. +32 16 345970, fax +32 16 345934
| | - David Feldman
- Dept. of Medicine, Division of Endocrinology, Stanford University School of Medicine 300 Pasteur Drive, Stanford, CA 94305-5103, USA, tel: 650-725-2910, fax: 650-725-7085
| | - Annemieke Verstuyf
- Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Herestraat 49 bus 901 O&NI, Leuven, Belgium, tel. +32 16 346209, fax +32 16 345934
| |
Collapse
|